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INTRODUCTION: The acronym PHACES describes the association of posterior fossa malformations, facial
hemangiomas, arterial anomalies (cardiovascular or cerebrovascular), coarctation of the aorta and car-
diac defects, eye abnormalities, and sternal or ventral defects. In this study we report on 6 patients
affected by the PHACES syndrome and showing 34 intraoral hemangiomas (IH), treated by diode laser
photocoagulation (DLP).
CASE PRESENTATION: IH appeared as red-bluish soft masses, smooth or lobulated, from a few millimetre
to several centimetres in size, covered by intact mucosa and blanching on pressure. IHs were treated
by DLP with 320m ﬁbres at a wavelength of 800±10nm. The diode laser techniques applied were:
Transmucosal DLP (DLTP), a no-contact technique in which laser energy is delivered by a ﬂexible optic
quartz ﬁber, which is kept 2–3mm apart from the lesion, and Intralesional DLP (DLIP), in which the
ﬁbre is introduced into the lesion through a transmucosal access. DLTP was used for 20 ﬂat, superﬁcial
IHs and, after a variable number of laser sessions (average=3) depending on the size of the lesion, 65%
completely regressed, while in the remaining 35% shrinkage of the lesion was achieved with minor and
few complications.
The remaining 14 deep/multi-lobulated IHs were treated by DLIP, resulting in complete regression of
79% of them.
CONCLUSIONS: DLP techniques are an effective and minimally invasive procedure for IH in patients with
PHACES, in consideration of the multiple lesions to treat, of the necessity of multiple interventions and
the higher compliance of the patients.
© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
PHACES is an acronym which refers to a rare syndrome char-
acterized by Posterior fossa defects, facial hemangiomas, arterial
lesions, cardiac abnormalities, eye anomalies and sternal cleft [1,2].
Firstly described by Frieden in 1996 [1], this syndrome shows
predilection for the female gender (M:F =9:1) [3,4]; there is no
evidence of familial tendency [5].
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Single/multiple facial hemangiomas are the most impor-
tant clinical manifestation of PHACES. Hemangiomas manifest
during the ﬁrst weeks of life as teleangiectasias or erythema-
tous plaques; subsequently, they increase in size (>5 cm), and
converge together, occupying one or more distinct segments:
fronto-temporal, maxillary, mandibular or fronto-nasal [6]. In 80%
of the cases, hemangiomas in the mandibular region are associ-
atedwith sternal clefts [7] and cardiovascular abnormalities [2,7,8].
Hemangiomas could completely or partially regress during the ﬁrst
decade, thus acquiring a port-wine like aspect.
The most common extracutaneous features are: cerebrovascu-
lar, structural brain and cardiovascular abnormalities [9].
Cerebrovascular anomalies consist in abnormalities of major
cerebral arteries and are divided into four categories: dysplasia,
narrowing, aberrant course/origin and persistence of embryonic
anastomoses [8].
A spectrum of congenital structural brain abnormalities have
been described in the PHACES syndrome, the most common of
which involving the cranial posterior fossa [8].
http://dx.doi.org/10.1016/j.ijscr.2015.03.045
2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Diagnostic criteria for PHACES syndrome.
Organ system Major criteria Minor criteria
Cerebrovascular Anomalies of major cerebral arteries: Persistent embryonic artery other than trigeminal artery:
Dysplasiaa of the large cerebral arteriesb Proatlantal intersegmental artery (types 1 and 2)
Arterial stenosis or occlusion with or without moyamoya collaterals Primitive hypoglossal artery
Primitive otic artery
Absence or moderate to severe hypoplasia of the large cerebral arteries
Aberrant origin or course of the large cerebral arteries
Persistent trigeminal artery
Saccular aneurysms of any cerebral arteries
Structural
brain
Posterior fossa anomaly Enhancing extra-axial lesion with features consistent with
intracranial hemangioma
Dandy-Walker complex Midline anomalyc
Unilateral/bilateral cerebellar hypoplasia/dysplasia Neuronal migration disorderd
Cardiovascular Aortic arch anomalies: Ventricular septal defect
Coarctation of aorta Right aortic arch (double aortic arch)
Dysplasiaa
Aneurysm
Aberrant origin of the subclavian artery with or without a vascular ring
Ocular Posterior segment abnormalities: Anterior segment abnormalities:
Persistent fetal vasculature (persistent hyperplastic primary vitreous) Sclerocornea
Cataract
Coloboma
Retinal vascular anomalies Microphtalmia
Morning Glory disc anomaly
Optic nerve hypoplasia
Peripapillary staphyloma
Coloboma
Ventral or midline Sternal defect Hypopituitarism
Sternal cleft Ectopic thyroid
Supraumbilicam raphe
Sterna defects
a Includes kinking, looping, tortuosity, and/or dolichoectasia.
b Internal carotid artery, middle cerebral artery, posterior cerebral artery, or vertebrobasial system.
c Callosal agenesis or dysgenesis, septum pellucidum agenesis, pituitary malformation, or pituitary ectopia.
d Polymicrogyria, cortical dysplasia, or gray matter hetrotopia.
Fig. 1. IH on the right cheek before (1a) and after Diode Laser Transmucosal Photocoagulation (1b).
Fig. 2. A gingival lesion in region 2.1–1.8 before laser treatment (2a), after 2 Diode Laser Intralesional Photocoagulation sessions (2b) and after complete healing (2c).
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Fig. 3. (a) and (b). Case 1: haemangioma of lower lip before and after Diode Laser Intralesional Photocoagulation. (c) and (d). Case 2: haemangioma of upper lip before and
after Diode Laser Intralesional Photocoagulation.
The most important cardiovascular anomaly associated with
PHACES is coarctation of the aorta, which occurs in 14.5% of the
affected patients [8]. Abnormalities of the eye are rare and most
frequently consist in microphthalmia and exophtalmo [9,10].
Ventral development defects consist of sternal clefting and
supraumbilical abdominal raphe [10].
Other extracutaneous manifestation of PHACES syndrome is
intraoral haemangioma (IH), which has been only occasionally
reported in the English literature.
According to the consensus statement on diagnostic criteria for
PHACES syndrome, the diagnosis requires the presence of segmen-
tal haemangioma of the head, greater than 5 cm, plus one major
criterion or 2 minor criteria, as illustrated in Table 1 [10].
The PHACES syndromemay show variable clinical presentation,
according to amajor andaminorphenotype, the formerbeing char-
acterizedbyseveral life-threateningabnormalities,whichcouldkill
the patient within the ﬁrst years of life, the latter manifesting less
serious anomalies, which allow patients to reach adulthood.
This work was aimed at describing the clinical features of the
vascular lesions occurring in 6 young patients affected by the
PHACES syndrome, and to illustrate the efﬁcacy of diode laser pho-
tocoagulation for the treatment of IH.
2. Case presentation
This studywas carried out in accordance with the code of ethics
of the world medical association (Declaration of Helsinki). The
patients released informed consent on diagnostic and therapeu-
tic procedures and for the possible use of biological samples for
research purposes.
In this study we report the cases of 6 PHACES patients (aver-
age age: 17,5 years), 2 males and 4 females, who collectively were
affected by 34 Intraoral Hemangiomas.
IHs appeared as red-bluish soft masses, smooth or lobulated,
from few millimetres to several centimetres, covered by intact
mucosa andblanchingonpressure. As such lesionsproducedbleed-
ing, functional and aesthetic/psychological problems, they were
treated with diode laser (GaAlAs - A2G Laser “Surgery 35”) with
a ﬂexible optic quartz ﬁbre of 320m, at a 800±10nm wave-
length by either diode laser transmucosal photocoagulation (DLTP)
or diode laser intralesional photocoagulation (DLIP).
Patients were treated under local anaesthesia without
adrenaline in multiple sessions. The laser was used in pulsed
mode (t-on 190ms/t-off 250ms) at the power of 9W. With the
DLTP technique, the laser source was kept 2–3mm apart from the
lesion, and moved slowly over the lesion.
With theDLIP technique the ﬁbrewas introduced into the lesion
and a radial pattern of laser energy was delivered, staying at least
5mm below the mucosal surface.
Before, during and after the laser sessions, cool packs were used
to avoid tissue thermal damage. Each session endedwith the appli-
cation of a gel made of hyaluronic acid and amino acids.
Overall, 34 IHswere detected, 20 of which, located on the fornix
and palate (5), tongue (4), ﬂoor of themouth (2), cheek (3) and gin-
giva (1) appeared as ﬂat, superﬁcial/reddish lesions; the remaining
14 IHs (lower lip: 4, upper lip: 4, fornix: 1, gingiva: 2 and cheek: 3)
appeared as deep,multi-lobulated bluish lesions. 3 IHs of the lower
lip and 2 of the tongue also showed ulceration and bleeding.
The ﬁrst 20 lesions treated by DLTP, showed slight post-
operatory pain, bleeding and oedema (15%) with low incidence
(5%) of complications (ulceration). After a variable number of laser
sessions (average=3) depending on the size of the lesions, 65% of
such lesions (gingiva: 1, tongue: 3, cheek: 2, fornix: 3 and palate: 4)
completely regressed, while the remaining 35% showed consistent
shrinkage with minor/absent complications (Fig. 1).
Post-operatory pain, bleeding and oedema were noticed in
patients affected by 6 of the 14 deep/multi-lobulated bluish IHs
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treated by DLIP. After a variable number of DLIP sessions (aver-
age =4), 79% (lower lip: 4, upper lip: 3, 1 on fornix, gingiva: 1
and cheek: 2) completely regressed, the remaining 21% having
presented shrinkage of the lesions and reduced complications
(Figs. 2 and 3). The follow-up period after the treatment was 18–72
months (average: 45months) with no evidence of recurrences of
the healed lesions.
3. Discussion
Facial hemangiomas are the most common PHACES syndrome
features. One of the most common extracutaneous localizations
of hemangiomas is the oral cavity, although rarely reported in
the English literature. PHACES IHs, like those in non-syndromic
patients, appear as red-bluish soft masses, smooth or lobulated,
often covered by intact mucosa [12]. Those located on lower lip
are at greater risk of complications (ulceration) [11]. In the current
report, 8 lesions occurred on the lips (4 lower and 4 upper), 6 on the
cheek and fornix, 5 on the palate, 4 on the tongue, 3 on the gingiva
and 2 on the ﬂoor of the mouth.
In the past years, a lot of surgical and non-surgical treatments
were tested for the management of hemangiomas. In view of
the haemorrhagic risk and high invasiveness related to surgical
excision, attentionwas paid to the possible alternative use of phar-
macological and/orminimally invasive interventions. Several drugs
have been tested, such as: propranolol [13,14], steroids [15], vin-
cristine [16] and bleomycin [17], which were proved effective on
hemangiomas in their proliferative phase, and recommended in
paediatric patients affected by PHACES syndrome. Laser photoco-
agulation has been considered an effective andnon-invasive option
for the treatment of adult PHACES patients with IHs without rele-
vant side effects and toxicity [18,19].
In view of hemangiomas containing high amounts of
haemoglobin absorbing in the spectral range of about
400–1100nm, Diode Laser with a wavelength of 800±10nm
was chosen because of its afﬁnity to oxyhaemoglobin, producing
photothermolysis, erythrocytes microagglutination and vessel
obliteration.
Thediode laser therapeutic approach to vascular lesions is based
on different techniques, such as transmucosal photocoagulation
(DLTP) or intralesional photocoagulation (DLIP). DLTP, preferred for
ﬂat superﬁcial/reddish IH, being a no contact technique, resulted a
minimally invasive treatment, with high rate of complete regres-
sion (65%), low incidence of post-operatory pain, bleeding and
oedema (15%). The DLIP technique, though at higher risk for post-
operatory pain, bleeding and oedema, in comparison with DLTP
(42,85%), was chosen for deeper lesions and resulted in complete
regression of 79% of the lesions.
The additional use of the gel compound of hyaluronic acid
and amino acids reset to zero post-operatory complications and
allowed faster healing of the lesions.
4. Conclusions
Diode laser photocoagulation techniques have been proved a
very effective and minimally invasive treatment for PHACES IHs,
considering the presence of several concomitant lesions and the
necessity of numerous interventions.
Conﬂict of interest
All authors disclose any ﬁnancial and personal relationships
withotherpeople or organizations that could inappropriately inﬂu-
ence (bias) their work.
Sources of funding
All Authors declare no sources of funding or any study sponsors.
Ethical approval
This studywas carried out in accordance with the code of ethics
of the world medical association (Declaration of Helsinki) and
approved by our institution ethical committee (study nr 4576 –
Prot. 1443/C.E.). The patients released informed consent on diag-
nostic and therapeutic procedures and possible use of biologic
samples for research purposes.
Consent
Thepatients released informed consent ondiagnostic and thera-
peutic proceduresand possible use of biologic samples for research
purposes.
Authors contribution
Gianfranco Favia: study concept or design, data collection, data
analysis or interpretation, writing the paper, ﬁnal revision.
Luisa Limongelli: study concept or design, writing the paper.
Angela Tempesta: study concept or design, writing the paper.
Matteo Favia: study concept or design, writing the paper.
EugenioMaiorano: study concept or design, data collection, data
analysis or interpretation, writing the paper, ﬁnal revision.
Guarantor
The corresponding author is the guarantor of submission.
Ethical standards
We hereby declare that this paper has not been previously pub-
lished or submitted elsewhere,
the authors have read and approved its content and all authors
do not have competing interest to declare.
Also,
- The work compiles with the ethical policies of the journal.
- It has been conducted under internationally accepted ethical
standards.
- All diagnostic and therapeutic procedures were carried out
according to “standard good clinical practice”.
- No experimental procedures were carried out that would
require approval by an ethical committee.
-Data fromall patients included in this studywere treatedanon-
imously and the patients released informed consent for the use of
such data for scientiﬁc publication.
References
[1] I.J. Frieden, V. Reese, D. Cohen, PHACE syndrome: the association of posterior
fossa brain malformations, hemangiomas, arterial anomalies, coarctation of
the aorta and cardiac defects, and eye abnormalities, Arch. Dermatol. 132
(1996) 307–311.
[2] D.W. Metry, C.F. Dowd, A.J. Barkovich, I.J. Frieden, The many faces of PHACE
syndrome, J. Pediatr. 139 (2001) 117–123.
[3] D.W. Metry, D.H. Siegel, R.M. Cordisco, E. Pope, J. Prendiville, B.A. Drolet, et al.,
A comparison of disease severity among affected male versus female patient
with PHACES Syndrome, J. Am. Acad. Dermatol. 58 (2008) 81–87.
[4] S.S. Arora, B.M. Plato, R.J. Sattenberg, R.K. Downs, K.S. Remmel, J.O.
Heidenreich, Adult presentation of PHACES syndrome, Interv. Neuroradiol. 17
(2011) 137–146.
[5] J.H. Levin, S.G. Kaler, Non-random maternal X-chromosome inactivation
associated with PHACES, Clin. Genet. 72 (2007) 345–350.
CASE REPORT – OPEN ACCESS
128 G. Favia et al. / International Journal of Surgery Case Reports 11 (2015) 124–128
[6] A.N. Haggstrom, E.J. Lammer, R.A. Schneider, R. Marcucio, I.J. Frieden, Pattern
of infantile hemangiomas: new clues to hemangioma pathogenesis and
embryonic facial development, Pediatrics 117 (2006) 698–703.
[7] D.W. Metry, A.N. Haggstrom, B.A. Drolet, E. Baselga, S. Chamlin, M. Garzon,
et al., A prospective study of PHACE syndrome in infantile hemangiomas:
demographic features, clinical ﬁndings, and complication, Am. J. Med. Genet.
140A (2006) 975–986.
[8] D. Metry, G. Heyer, C. Hess, M. Garzon, A.N. Haggstrom, P. Frommelt, et al.,
Consensus statement on diagnostic criteria for PHACE syndrome, Pediatrics
124 (2009) 1447–1456.
[9] K. Brandon, P. Burrows, C. Hess, D. Metry, Arteriovenous malformation a rare
manifestation of PHACE syndrome, Pediatr. Derm. 28 (2001) 180–184.
[10] D.A. Hartemink, Y.E. Chiu, B. Drolet, J.E. Kerschner, PHACES syndrome: a
review, Int. J. Pediatr. Otorhinolaryngol. 73 (2009) 181–187.
[11] S.L. Chamlin, A.N. Haggstrom, B. Drolet, E. Baselga, I.J. Frieden, M. Garzon,
et al., Multicenter prospective study of ulcerated hemangiomas, Pediatrics
151 (2007) 684–689.
[12] J.S. Gill, S. Gill, A. Bhardawaj, H.S. Grover, Oral haemangioma, Case Rep. Med.
(2012) 347939.
[13] A.L. Marqueling, V. Oza, I.J. Frieden, K.B. Puttgen, Propranolol and infantile
hemangiomasfour years later: a systematic review, Pediatr. Dermatol. 30
(2013) 182–191.
[14] T. Solomon, J. Ninnis, D. Deming, T.A. Merritt, A. Hopper, Use of propranolol
for treatment of hemangiomas in PHACE syndrome, J. Perinatol. 31 (2011)
739–741.
[15] A. Izadpanah, A. Izadpanah, J. Kanevsky, E. Belzile, K. Schwarz, Propranolol
versuscorticosteroids in the treatment of infantile hemangioma: a systematic
review and meta-analysis, Plast. Reconstr. Surg. 131 (2013)
601–613.
[16] R.S. Glade, K. Vinson, D. Becton, S. Bhutta, L.M. Buckmiller, Management of
complicated hemangiomas with vincristine/vinblastine: quantitative
response to therapy using MRI, Int. J. Pediatr. Otorhinolaryngol. 74 (2013)
1221–1225.
[17] Q.F. Luo, F.Y. Zhao, The effects of Bleomycin A5 oninfantile maxillofacial
haemangioma, Head Face Med. 7 (2011) 11.
[18] A. Vesnaver, D.A. Dovsak, Treatment of vascular lesions in the head and
neckusing Nd:YAG laser, J. Cranio-Maxillo-Fac. Surg. 34 (2006)
17–24.
[19] U. Romeo, A. Del Vecchio, C. Russo, G. Palaia, G. Gaimari, J.
Arnabat-Dominquez, et al., Laser treatment of 13 benign oral vascular
lesionsby three different surgical techniques, Med. Oral Patol. Oral Cir. Bucal.
18 (2013) 279–284.
Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which
permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are
credited.
